Immuneering (NASDAQ:IMRX) Stock Price Up 5.9%

Immuneering Corp (NASDAQ:IMRX) shares rose 5.9% during trading on Tuesday . The stock traded as high as $26.80 and last traded at $26.75. Approximately 3,360 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 167,790 shares. The stock had previously closed at $25.27.

A number of analysts have recently issued reports on IMRX shares. Cowen started coverage on shares of Immuneering in a research report on Tuesday, August 24th. They issued an “outperform” rating for the company. Morgan Stanley started coverage on shares of Immuneering in a research report on Tuesday, August 24th. They issued an “equal weight” rating and a $39.00 price target for the company. Jefferies Financial Group started coverage on shares of Immuneering in a research report on Tuesday, August 24th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Guggenheim started coverage on shares of Immuneering in a research report on Tuesday, August 24th. They issued a “buy” rating and a $42.00 price target for the company.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Thursday, September 9th. The company reported ($1.61) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.66) by $0.05. On average, equities research analysts forecast that Immuneering Corp will post -3.28 EPS for the current year.

Immuneering Company Profile (NASDAQ:IMRX)

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company’s product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

Featured Article: Mutual funds are not immune from market timing

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.